Feels like a boring but steady winner.
Healthcare and insurance are still the bedrock, but I’m uneasy about the capex timing and regulatory tailwinds. If CMS leans heavier on cost controls, $UNH’s margins could slip. Feels like a solid base, but not a runaway.
For a long-term hold, how do you weigh the mix of healthcare growth and insurance stability at $UNH, especially with the 2024-25 capex plan and potential regulatory shifts? Does the dividend growth track still justify the premium?
Everyone keeps saying “AI buzzword” and “cycles,” but leveraged ETFs don’t follow cycles. They amplify noise. If tariffs or inventory cycles reverse, SOXL can unwind fast. Momentum can’t save you from regime shifts.
Rates still elevated and dollar firm—why should leveraged semis keep outperforming? Tariff risk plus currency drag usually kills SOXL’s compounding.
For semis, is this rally driven by AI chips, foundry demand, or just memory/PC refreshes? How much of NVDA’s strength is translating to AMD, MU, or INFY? If tariffs ease, do memory makers like MU or MU outperform?
Feels like every time we get a 'teflon' call, the market just resets expectations. CVNA’s got potential, but the hype cycles keep getting out of hand. I’m tired of chasing these narratives before fundamentals catch up.
Not convinced—teflon hype usually fades fast.
New to this, but Teflon seems like a protective layer for CVNA. Wondering how much of this is real tech versus marketing.
